← Back to Search

Other

CRD-740 for Heart Failure (CARDINAL-HF Trial)

Phase 2
Waitlist Available
Research Sponsored by Cardurion Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights

CARDINAL-HF Trial Summary

This trial is testing a drug to see if it can help people with two types of heart failure.

Eligible Conditions
  • Heart Failure
  • Cardiovascular Disease
  • Heart Disease

CARDINAL-HF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A: The change from baseline (Day -1) in plasma cGMP at Week 4.
Part B: The change from baseline (Day 1) in NT-proBNP at Week 12.
Secondary outcome measures
Part B: The change from baseline (Day 1) in plasma BNP at Week 12.
Part B: The change from baseline (Day 1) in plasma cGMP at Week 12.
Part B: The change from baseline (Day 1) in the KCCQ-23-CS at Week 12.
+1 more
Other outcome measures
Part A: The change in NT-proBNP from baseline (Day 1) to Week 2, from Week 2 to Week 4, and from Week 2 to Week 12.

CARDINAL-HF Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CRD-740Experimental Treatment1 Intervention
Part A: Participants in Part A randomly assigned to this arm will take CRD-740 twice daily at two ascending dose levels over 12 weeks. Part B: Participants in Part B randomly assigned to this arm will take CRD-740 twice daily at a single dose level over 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Part A: Participants in Part A randomly assigned to this arm will take placebo twice daily at two ascending dose levels over 12 weeks. Part B: Participants in Part B randomly assigned to this arm will take placebo twice daily at a single dose level over 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CRD-740
2022
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Cardurion Pharmaceuticals, Inc.Lead Sponsor
4 Previous Clinical Trials
672 Total Patients Enrolled
3 Trials studying Heart Failure
660 Patients Enrolled for Heart Failure
Elizabeth Moore, DNP, CPNP-AC, CPNStudy DirectorSenior Director, Clinical Research
Pirouz Shamszad, MDStudy DirectorExecutive Director, Clinical Research

Media Library

CRD-740 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05409183 — Phase 2
Heart Failure Research Study Groups: Placebo, CRD-740
Heart Failure Clinical Trial 2023: CRD-740 Highlights & Side Effects. Trial Name: NCT05409183 — Phase 2
CRD-740 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05409183 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has CRD-740 been cleared by the FDA for use?

"CRD-740's safety is based on data from a Phase 2 trial, which means that while there is evidence suggesting it is safe, there is none yet supporting its efficacy."

Answered by AI

To date, how many people have enroll in this research project?

"Yes, you are correct. The most recent information on clinicaltrials.gov shows that this study is ongoing and presently recruiting participants. This trial was first posted on May 26th, 2020 and was updated September 28th, 2020. They are looking for 660 people to participate across 31 different locations."

Answered by AI

How many research sites are involved in this project?

"To minimize travel for potential participants, this study is enrolling patients at 31 locations. A few select sites include Atlanta, Winfield and Vancouver with the remaining 28 clinical trial centres being based in other nearby cities."

Answered by AI

Is this a fully enrolled clinical trial or are there opportunities for new participants?

"This trial, as indicated by clinicaltrials.gov, is looking for candidates at this time. The original posting date was 5/26/2022, with the most recent edit on 9/28/2022."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
Indiana
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Cardurion Investigative Site
How many prior treatments have patients received?
1

Why did patients apply to this trial?

To help find a cure.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How long is screening and clinical trial? Is there compensation for trial?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Effectiveness of CRD-740 in Heart Failure
2022. "Effectiveness of CRD-740 in Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05409183.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top